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Abstract.  We have shown previously that chick mus- 
cle cells transformed with Rous sarcoma virus are un- 
able to form clusters of acetylcholine receptors 
(AChRs) (Anthony, D.  T., S.  M.  Schuetze, and L.  L. 
Rubin.  1984.  Proc. Natl.  Acad.  Sci.  USA. 81:2265- 
2269)  and are missing a  37-KD tropomyosin-like pro- 
tein (TM-2)  (Anthony, D.  T.,  R. J.  Jacobs-Cohen, G. 
Marazzi, and L. L. Rubin.  1988.  J.  Cell Biol. 
106:1713-1721).  In an attempt to clarify the role of 
TM-2  in the formation and/or maintenance of AChR 
clusters, we have microinjected a  monoclonal antibody 
specific for TM-2 (D3-16)  into normal chick muscle 
cells in culture.  D3-16  injection blocks the formation 
of new clusters but does not affect the preexisting 
ones. In addition, TM-2  is concentrated at rat neu- 
romuscular junctions. These data suggest that TM-2 
may play an important role in promoting the formation 
of AChR clusters. 
ETYLCHOLINE receptors  (AChRs) ~ are  highly con- 
centrated at the adult vertebrate neuromuscular  junc- 
tion. The preferential localization of AChRs at the 
postsynaptic membrane occurs during the early stages  of 
nerve-muscle synapse formation (for reviews see 11, 13, 27). 
This region is also characterized by an intricate submem- 
branous cytoskeletal network. In the last few years, much 
work has focused on the possible functional relationship be- 
tween the components of this cytoskeletal network and the 
organization of the postsynaptic region. 
The  search  for  cytoplasmic  events  involved  in  AChR 
clustering has been predominantly immunocytochemical to 
this point.  A  variety of cytoskeletal molecules have been 
found to be concentrated at the vertebrate neuromuscular 
junction or in association with AChR aggregates on cultured 
mammalian or avian muscle fibers (for review see 15). These 
include nonmuscle actin, various actin-binding proteins, and 
a 43-kD AChR-associated protein thought to have the ability 
to bind to actin and to the/3 subunit of AChR (4-8, 10, 16, 19, 
22, 23, 26, 28, 30). It is likely that these proteins are involved 
in the organization of the subcluster region, but no direct evi- 
dence has yet been provided. Since the junctional region has 
many cellular specializations, including postsynaptic mem- 
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brane folds and a characteristic set of muscle organelles (12), 
it is important to determine which elements are involved in 
clustering, rather than in these other specializations. 
We have previously observed that cultured chick muscle 
cells transformed by Rous sarcoma virus (RSV) are not able 
to form AChR clusters even in the presence of a  Torpedo 
electric tissue extract that enhances AChR clustering in nor- 
mal myotubes (1). Recently, we have described a novel 37-kD 
cytoplasmic muscle component that reacts  with an  anti- 
tropomyosin antiserum. This protein, which we have termed 
tropomyosin 2 (TM-2),  is greatly decreased in RSV-trans- 
formed chick muscle cells (2).  We have also generated a 
monoclonal antibody (D3-16) against TM-2 (2). To demon- 
strate a functional association between the presence of TM-2 
and the formation and/or maintenance of AChR clusters, we 
microinjected D3-16 into normal cultured chick muscle cells. 
Injection of D3-16 blocked the formation of AChR clusters. 
We also used D3-16 to show that TM-2 is enriched at rat neu- 
romuscular junctions. These data suggest that the 37-kD pro- 
tein participates in the process of receptor clustering. 
Materials and Methods 
Monoclonal Antibodies 
A  monocional antibody specific  for the 37-kD tropomyosin-like protein 
(D3-16) was produced as described previously (2). IgG was purified from 
hybridoma supernatant by absorption to a protein A-Sepharose 413 affinity 
column (Pharmacia Fine Chemicals, Piscataway,  N  J) and eluted with 50 
mM citrate buffer, pH 4, according to the manufacturer's conditions. Peak 
fractions were pooled, dialyzed in 10 mM Tris, pH 7.4, and concentrated 
on a Centricon 30 filter (Amicon Corp., Danvers, MA). The concentration 
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(Pierce Chemical Co., Rockford, IL) (29) and was adjusted to 7 mg/ml; the 
antibodies were then sterilized through a 0.22-#m filter and kept at 4"C. 
Muscle Cell Culture 
Muscle cells were obtained by enzymatic dissociation of 1  l-d chick embryo 
leg muscle as described previously (14).  Cells were grown on collagen- 
coated coverslips in a growth medium consisting of MEM (Gibco Laborato- 
ties, Grand Island, NY) with 10% horse serum (Gibco Laboratories) and 
2% chick embryo extract in an atmosphere containing 5% CO2.  For some 
experiments, muscle cells were treated with an AChR cluster-inducing fac- 
tor (CF) isolated from Torpedo californica electric tissue using techniques 
already described (25). 
Microinjection 
Glass pipettes used in microinjection were made from Omega Dot tubing 
(internal diameter of 0.6 mm; Glass Company of America, Bargalntown, 
NJ) by two sequential pulls (244 and 188 V, respectively) with a vertical 
puller (David Kopf Instrument, Tujunja, CA). Pipettes were acid washed, 
sterilized in absolute ethanol (18), and kept under sterile conditions. During 
microinjection, cells were kept in a 1:1 mixture of  MEM/L-15 media (Gibco 
Laboratories) with 10% horse serum and 2% chick embryo extract. D3-16 
was pressure injected from a pipette containing 7 mg/ml of this antibody 
in 10 mM Tris. Control cells were pressure injected from pipettes filled with 
nonimmune  mouse  immunoglobulin  (Mlg)  (Sigma  Chemical  Co.,  St. 
Louis, MO) made up in 10 mM Tris at the same concentration as the D3-16 
solution. Based upon the results of Caaessmann and Graessmann (17) and 
assuming that we inject muscle cells at 20-#m intervals and that they are 
cylinders of 10 ~m diameter, we calculate that the final concentration of Ig 
in the cell is -o0.5-1 #M. After injection, cells were treated for 6 h with 
CF in growth medium and incubated for 1 h with rhodamine-conjugated 
~-bungarotoxin (Rh-c~Bgtx) prepared by the method of Ravdin and Axelrod 
(24) to localize AChRs. Cells were then fixed in methanol at  -20"C and 
labeled with fluorescein-conjugated goat anti-mouse lgG (Cappel Labora- 
tories, Malvern, PA) to identify the injected cells. Cells were examined with 
a microscope (Carl Zeiss, Inc., Thornwood, NY) equipped with phase and 
fluorescence optics. 
In some cases, cells were pretreated for 5-6 h with 5 mM sodium azide 
to disperse  the existing AChR clusters (4). Some cells were labeled and fixed 
after sodium azide treatment. Others were microinjected with D3-16, MIg, 
or with a monoelonal antitubulin antibody. This latter antibody is an IgG 
class antibody derived from a BALB/c mouse using similar procedures to 
those used to derive 1)3-16. Hybridoma cells were grown, and antibody was 
purified from the supernatant and concentrated  just as described for D3-16. 
As previously shown, the antitubulin antibody binds to tubulin but does not 
interfere with its function (9a, 10). The cells were then allowed to recover 
for 5-6 h in the presence of CF in growth medium and then labeled as de- 
scribed above. 
Morphometry 
To analyze in detail the number and size of AChR aggregates, myotubes 
were selected at random and filmed under fluorescent optics with a silicon- 
intensified instrument camera (Dage-MTI Inc., Wabash,  MI)  interfaced 
with a video cassette recorder (VC-9507,  NEC Home Electronics [U.S.A] 
Inc.,  Elk  Grove Village,  IL).  Myotube  segments and  bright Rh-c~Bgtx 
patches were traced from the video screen onto acetate sheets. Areas of 
patches and of myotube segments were measured by tracing their outlines 
on a digitizing tablet interfaced with a personal computer (IBM Instruments, 
Inc., Danbury, CT) using the MicroComp Planar Morphometry software 
(SMI, Inc., Atlanta, GA). Approximately 150 segments were analyzed for 
each treatment. Bright fluorescent patches of Rh-ctBgtx were defined as 
AChR aggregates when their area was between 12.5  and 25 #m  2 and as 
AChR clusters when their area was >25 #m  2. We then calculated the ratio 
between the number of  clusters (or aggregates) counted per segment and the 
area of the corresponding segment; this gave the number of clusters (or ag- 
gregates) per unit area. 
Immunocytochemistty 
Adult rat diaphragm or intercostal muscles were frozen in liquid nitrogan- 
cooled isopentane and mounted in OCT compound (Miles Scientific Die., 
Naterville, IL).  4-#m tissue sections were cut and mounted on gelatin- 
subbed slides. Slides were preincubated for 30 rain in MEM containing 10% 
horse serum or 1% BSA (Sigma Chemical Co.) and then incubated for 1 h 
at room tempemtare in either I)3-16 hybridoma supernatant or purified D3-16 
lgG diluted in MEM plus horse serum. Sections were rinsed in PBS and 
incubated in Rh-aBgtx and fluorescein-conjugated  goat anti-mouse IgG for 
1 h at room temperature. Sections were rinsed again in PBS and mounted 
in UV-inert mounting compound (Atomergic Chemetals Corp., Plalnview, 
NY) and photographed as described previously (2). 
Results 
Microinjection of  Normal Cells 
To determine the role of TM-2 in the clustering process, we 
injected normal cultured chick muscle cells with D3-16.  We 
assumed that antibody binding to TM-2 would subsequently 
affect the ability of TM-2 to interact with other cytoskeletal 
components,  thereby  blocking its function.  We used chick 
myotubes for these experiments because of our prior study 
on RSV-transformed chick cells (1). Cells were injected be- 
tween days 5 and 7 after plating when the probability of spon- 
taneous cluster formation is highest. It has been shown previ- 
ously that  chick or rat muscle  cells  in culture exhibit an 
increase in the number of AChR clusters when treated with 
a factor (or factors) derived from the extracellular matrix of 
Torpedo electric tissue (25,  31). After microinjection, cells 
were treated with Torpedo CF to test whether the antibody 
inhibited  the formation of new AChR clusters. 
Results  were analyzed  initially  by  immunofluorescence 
(Fig. 1), and subsequently these data were subjected to quan- 
titative morphometric analysis. Using a planar morphometry 
system, we measured the areas of rhodamine-positive bright 
patches  and  of  myotube  segments  (see  Materials  and 
Methods).  We analyzed cells exposed to four different ex- 
perimental conditions: (a) noninjected, untreated cells; (b) 
noninjected, CF-treated cells; (c) D3-16--injected,  CF-treated 
cells; and (d) MIg-injected, CF-treated cells. The distribu- 
tions of the frequencies of clusters and aggregates per unit 
area are presented in Figs. 2 and 3. Most noninjected, un- 
treated myotubes did not have any AChR clusters (Fig. 2). 
Nevertheless,  clusters  and  smaller  fluorescent Rh-aBgtx 
patches were observed in some cells. 
After 6 h of treatment with CF, the number of clusters per 
unit area increased markedly in the noninjected cells. Only 
a  few segments had no clusters.  To evaluate the effect of 
microinjection per se, we injected nonimmune MIg under 
the same conditions as for D3-16 (Fig. 1, e and f). As shown 
in Fig. 2, we observed that the ability of MIg-injected cells 
to respond to CF was only slightly diminished. In contrast, 
in D3-16-injected cells, treatment with CF did not increase 
the number of AChR clusters (Fig. 1, a-d, and Fig. 2). The 
distribution of cluster density was very similar to that of un- 
treated cells, suggesting that the binding of D3-16 to TM-2 
does not disrupt preexisting clusters but instead prevents the 
formation of new clusters induced by CE  There were no 
other obvious morphological effects on the injected cells. 
We also analyzed the density of aggregates (Fig. 3). D3- 
16-microinjected cells had a density of aggregates similar to 
that of the untreated cells. After a 6-h treatment with CF, the 
number of segments without aggregates decreased in both 
noninjected and MIg-injected cells. In contrast, the number 
of segments without aggregates remained very high in un- 
treated cells and D3-16-injected cells. 
We were also interested in determining whether the size 
of AChR clusters was modified by any of the four different 
The Journal  of Cell Biology,  Volume 109, 1989  2338 Figure L Effect of D3-16 microinjection on AChR clusters formation. After injection, cells were treated for 6 h with CF, incubated for 
60 min with Rh-ccBgtx  to localize AChRs (a, c, and e), fixed in methanol at -200C, and labeled with fluorescein-conjugated  goat anti-mouse 
IgG to identify injected cells (b, d, and f). After a 6-h treatment with CF, no ACILR  dusters were observed in the bright D3-16--injected 
cells, whereas several clusters and aggregates were present on the nearby noninjected cell (a-d). The MIg-injected cell was still able to 
cluster AChRs after treatment with CF (e and f). The Rh-t~Bgtx staining pattern of this cell is comparable with that of the noninjected 
cells. Bar, 10 tLm. 
experimental conditions. We therefore determined the distri- 
bution of cluster size on 150 muscle segments for each ex- 
perimental condition. Under all four conditions, the majority 
(80-90%) of AChR clusters were between 25 and 75 #m  2. 
5 % of the clusters (total number of 692) in noninjected and 
MIg-injected cells (516 clusters) treated with CF were very 
large (>125/~m2). We never observed such large clusters in 
D3-16-injected cells (192 clusters) and only saw 1 large clus- 
ter out of 216 in untreated cells. 
Microinjection of  Myotubes Treated with Sodium Azide 
From these observations, we assumed that blocking TM-2 
did not affect the preexisting clusters but prevented the in- 
duction of new clusters caused by the treatment with CE To 
distinguish more easily between the effect of microinjection 
on preexisting clusters and on new cluster formation, we 
wanted to examine cells that had few or no clusters at the start 
of the experiment. A previous study (4) demonstrated that 
AChR clusters are dispersed by treating cells with a meta- 
bolic inhibitor such as sodium azide. This process is revers- 
ible, and cells are able to reform clusters rapidly after re- 
placement of medium. We treated cells for 5 h with 5 mM 
sodium  azide  before microinjection.  After  sodium  azide 
treatment, most of the cells did not have any clusters, al- 
though occasional small aggregates were present (Fig. 4  a 
and Table I). After changing the medium, the cells were al- 
lowed to recover for 6 h in the presence of CE After recov- 
ery, noninjected cells had clusters and large aggregates (Fig. 
4 b). Control antitubulin- and MIg-injected cells were also 
able to reform clusters  during the recovery from sodium 
azide treatment (Fig. 4, e-h). Cells injected with D3-16 after 
sodium azide treatment did not have any clusters, although 
very small  aggregates were sometimes detected that were 
similar to those observed in cells labeled and fixed immedi- 
ately after dispersal of AChR clusters (Fig. 4, c and d). Taken 
together, these data suggest that D3-16 microinjection does 
block the formation of new clusters. 
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Figure 2. Distribution  of numbers of 
AChR dusters per unit area. Four dif- 
ferent experimental conditions were 
analyzed: noninjected, untreated cells 
(CF-); noninjected, CF-treated cells 
(C/~); nonimmune  MIg, CF-treated 
ceils  (MIg+/CF+); and  D3-16--in- 
jected,  CF-treated  cells  (D3-16÷/ 
Cb-*). Bright  fluorescent patches  of 
Rh-c~Bgtx were  considered as clus- 
ters when their area was >25 #m  2. 
We calculated  the ratio between the 
number of clusters observed in each 
segment and the area of the corre- 
sponding  segment.  We  then  multi- 
plied the values obtained by 104. Each 
dot  represents  a  my•tube segment 
with an assigned  density of AChR 
clusters. Dots at and beneath the zero 
line represent segments with no clus- 
ters at all. Most of the segments ana- 
lyzed in noninjected, untreated my•- 
tubes (CF-) do not have any clusters. 
The segments that did possess clus- 
ters had <10 clusters per unit area. 
Treatment with CF led to a marked 
increase in the number  of clusters per 
unit area in noninjected cells (CF  ~) 
and, although  to a lesser extent,  in 
MIg-injected cells (MIg÷  /CF~). Seg- 
ments with no clusters at all were less 
frequent. In contrast, D3-16--injected 
cells did not show an increase in AChR cluster numbers after treatment with CF (D3-16÷/CF+).  The distribution of clusters is very similar 
to the one observed in noninjected, untreated  cells, suggesting that the preexisting  clusters  were not disassembled. 
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Figure 3. Distribution  of the number 
of AChR aggregates per unit area (see 
legend  to Fig.  2).  Aggregates  were 
defined as bright Rh-aBgtx patches 
with an area between 12.5  and 25 
#m:. Note that  the number of seg- 
ments with no aggregates is very high 
in both noninjected, untreated cells 
(CF-) and D3-16-injected cells after 
treatment with CF (D3-16÷/CP"). In 
contrast, in noninjected cells (C/~) 
and MIg-injected  cells (MIg+/CF*), 
treatment with CF for 6 h led to a de- 
crease in the number of segments with 
no aggregates. 
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Results  of our  microinjection experiments  suggested  that 
TM-2 plays a role in the process of AChR clustering; there- 
fore, we examined its distribution in adult muscle using im- 
munocytochemistry on frozen sections of adult rat diaphragm 
and intercostal muscles. We found that TM-2 was distributed 
all along the lengths of the muscle fibers. However, it was 
most concentrated at the junctional region (Fig. 5, a and b). 
We did not observe any labeling along motor nerve processes. 
Our current efforts with  frozen sections made from adult 
chicken muscle have so far not revealed any obvious staining 
anywhere in the fiber despite the ability of D3-16 to label 
TM-2 in cultured chick myotubes. We know that TM-2 is 
present in chicken muscle based upon results with Western 
blots (2); thus, either the accessibility of TM-2 to D3-16 is 
different in chicken muscle or TM-2's antigenicity is lost dur- 
ing the preparation of the frozen sections. However, we note 
that its distribution in rat muscle concurs strongly with a pro- 
posed role of TM-2 in clustering. 
Discussion 
Our previous work established that chick muscle cells trans- 
formed with a temperature-sensitive mutant of RSV cannot 
cluster AChRs even when maintained at the nonpermissive 
temperature for transformation (1).  We examined possible 
differences between normal and RSV-transformed cells that 
might account for the inability of transformed cells to cluster 
AChRs.  We found that transformed cells showed greatly de- 
creased amounts of a nonmyofibrillar tropomyosin-like mol- 
ecule, TM-2 (2). In the experiments described in this report, 
we present a functional assay that suggests that TM-2 partici- 
pates in AChR clustering. Microinjecting a monoclonal anti- 
body specific for this molecule (D3-16) interferes with new 
cluster formation. We calculated that the concentration of  an- 
tibody introduced into the cells was ,o0.5-1 #M.  Based on 
our recent unpublished results with microsequencing of TM- 
2 and on the estimates of Wojcieszyn et al. (32), we estimate 
the concentration of TM-2 to be ,02 #M.  We do not know 
how much of the TM-2 would have to be blocked by the anti- 
body to block clustering since we do not know, for instance, 
the proportion of TM-2 that participates in this process. It 
seems quite possible that the amount of injected D3-16 was 
sufficient to bind to a large fraction of the TM-2. The anti- 
body concentration is similar to that used on Western blots 
where D3-16 labels primarily TM-2, but also a 43-kD tropo- 
myosin-like protein (TM-1). Of course, we can't truly predict 
what the specificity of D3-16 would be after its introduction 
into the cell, but previous experience has suggested that other 
antibodies injected into cells under similar circumstances re- 
tain their specificity (20, 21). Also, we favor the explanation 
that it is TM-2, rather than TM-1, that plays a role in cluster- 
ing since the levels of TM-1 were not altered in virally trans- 
formed cells, but further experimentation will be needed to 
resolve this issue. 
The first set of experiments we described focused on cells 
that already had some clusters and that were subsequently 
treated with CF derived from Torpedo  electric tissue. Nonin- 
jected cells had a large increase in the number of clusters 
within  a  few  hours  of treatment  with  this  factor.  Cells 
microinjected  with  a  control  nonimmune  Ig  had  only  a 
slightly  decreased  capacity  to  form  new  AChR  clusters, 
probably due to minor cell damage resulting from microin- 
jection. Cells injected with D3-16,  however, showed a dra- 
matic reduction in their ability to cluster AChRs. In addition, 
very large clusters were never observed in either D3-16-in- 
jected or untreated cells. Changes were most marked 6-8 h 
after microinjection and decreased by 24 h, corresponding 
with the point at which we can no longer detect the presence 
of the injected antibody. There were no pronounced effects 
of the microinjection on general cell morphology, and cells 
survived for at least 24 h after injection. Also, the fact that 
microinjection seemed not to break up preexisting clusters 
argues against a generally deleterious effect of injection of 
any of the antibodies. 
We also examined the effects of injection on AChR ag- 
gregates. Previously, we have seen that these small patches 
of AChRs are not as stable as clusters and are not necessarily 
associated with immobile nuclei (12). Presumably, they rep- 
resent an intermediate stage in cluster formation, and we quan- 
tified them separately. Again, we found that D3-16-injected 
cells  had  more regions  free of aggregates than did  MIg- 
injected ones.  This further supports the notion that D3-16 
injection interferes with the process by which AChRs  ac- 
cumulate. 
D3-16-injected cells  had  some  clusters  after treatment 
with CE We interpret these to be clusters that were already 
present before injection.  Evidence consistent with this in- 
cludes our observation that cells both injected with D3-16 
and treated with CF had approximately the same number of 
clusters and aggregates as untreated cells. The fact that the 
size distribution of clusters in the two types of cells was simi- 
lar (i.e., very large clusters were absent from both) is consis- 
tent with this interpretation. In addition, clusters labeled be- 
fore microinjection were still present 4 h after microinjection 
(data not shown). 
A  strong indication that D3-16 microinjection blocks the 
formation of new clusters derives from observations of cells 
incubated with sodium azide. This treatment had been shown 
previously by Bloch (4) to disrupt clusters reversibly. Cells 
treated with sodium azide and then injected with either of 
two control Igs (nonimmune IgG or an antitubulin monoclo- 
hal made and concentrated in the same way as D3-16) formed 
new  clusters  after  sodium  azide  washout;  however,  cells 
microinjected with D3-16 before sodium azide removal were 
unable to form new clusters. The ability of D3-16 microin- 
jection  to  block  new  cluster  formation  without  affecting 
preexisting clusters might suggest that (a) once clusters are 
formed, TM-2 does not play any role in their maintenance; 
(b) once clusters are formed, the epitope is no longer accessi- 
ble to the antibody; or (c) TM-2 is assembled rapidly during 
cluster formation but its disassembly is slow so that we can- 
not observe disruption of preexisting clusters 6 h after a sin- 
gle microinjection. 
Evidence consistent  with  the  putative role of TM-2  in 
AChR clustering is the observation that it is concentrated 
(but not exclusively localized) at mammalian neuromuscular 
junctions. Preliminary ultrastructural experiments confirm a 
postsynaptic localization of this molecule and also suggest 
that this preferential localization is not due simply to an in- 
creased surface area in the junctional region (Fumagalli, G., 
G.  Marazzi, and L.  L.  Rubin,  unpublished observations). 
Despite the fact that Western blot analysis using D3-16 has 
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Number of clusters 
Condition  per segment 
I.  Azide treated and fixed 
2.  Azide removed, noninjected 
3.  Azide removed, MIg injected 
4.  Azide removed, antitubulin injected 
5.  Azide removed, D3-16 injected 
0.28  +  0.03  (68) 
2.33  +  0.21  (45) 
2.32  +  0.27  (49) 
2.15  +  0.29  (38) 
0.35  +  0.13  (45) 
Cells were treated as described in the legend to Fig. 4. After azide treatment, 
cells were either fixed immediately (condition 1 ), treated with CF (condition 
2),  or microinjected  and  treated  with CF (conditions  3-5).  The  number  of 
clusters and large aggregates per segment was then determined.  Entries in the 
table represent the mean number of clusters per segment  -l- SEM.  The num- 
bers in parentheses are the number of segments for each condition.  D3-16 in- 
jection  blocks  the  recovery  normally  seen  after  azide  washout,  whereas 
injection of two control  antibodies has no significant effect. 
shown that TM-2 is present in adult chicken muscle (2), we 
do not know its distribution in that tissue because D3-16 does 
not label frozen sections of chicken muscle. In a previous re- 
port, we showed that TM-2 is present along the entire length 
of rat and chick cultured muscle fibers and is not concen- 
trated near AChR clusters (2). The difference between cul- 
tured embryonic myotubes and adult innervated muscle fibers 
may reflect the greater degree of maturity of the adult sub- 
cluster region. Alternatively, the relatively large amounts of 
TM-2 seen away from clusters in cultured muscle fibers may 
reflect its participation in processes that are more prevalent 
in embryonic than in adult muscle. For example, as we sug- 
gested previously (2), assembly of myofibrils may be such 
a  process. 
How might TM-2 participate in AChR clustering? Several 
investigators have demonstrated a high concentration of actin 
beneath AChR clusters in cell culture or at the neuromuscu- 
lar junction (5,  10,  19, 22).  Since cluster formation appears 
to be blocked by cytochalasin D (12), it seems probable that 
this actin network contributes significantly to the process by 
which AChRs form stable aggregates. In other systems, it has 
been shown that tropomyosin can stabilize actin filaments by 
direct binding (3). Therefore, since TM-2 shares some prop- 
erties with tropomyosins, it might be essential for stabilizing 
actin filaments that are actively polymerizing under newly 
forming clusters and thus eventually serve as a scaffold for 
the  formation of AChR aggregates.  As we have also men- 
tioned, this subcluster scaffold is likely to be extensive, span- 
ning  the  sarcolemma  and  associated  organelles,  such  as 
nuclei and Golgi apparatus (12).  If the tropomyosin-like be- 
havior of TM-2 is confirmed (i.e., binding to actin), this will 
guide the  search  for other  structural  proteins that are  in- 
volved in the establishment of the neuromuscular junction 
region. 
In summary, we feel that we have provided three results 
consistent  with  a  role  for TM-2  in  clustering:  (a)  virally 
Figure 5. Immunofluorescence of  adult rat neuromuscular junctions 
stained with D3-16. Sections of rat diaphragm  were labeled with 
Rh-otBgtx (b) and D3-16 followed by fluorescein-conjugated goat 
anti-mouse IgG (a). Antibody labeling is concentrated at the junc- 
tional region but extends throughout the muscle fibers as well. Bar, 
10 #m. 
transformed cells with decreased amounts of this polypep- 
tide  cannot cluster AChRs;  (b)  TM-2  is  localized at  neu- 
romuscular junctions,  at least in adult rat muscle; and (c) 
microinjection of an antibody directed against TM-2 blocks 
the  ability  of cultured  muscle  cells  to  form  new  AChR 
clusters.  Our next set of experiments will be directed at in- 
troducing TM-2 into virally transformed cells to see if this 
enables them to cluster AChRs. This will strengthen the ar- 
gument for TM-2's participation in the clustering process. 
Figure 4.  Effect of microinjection  on cells recovering from azide treatment.  (a and b) Rh-t~Bgtx labeling after sodium azide treatment. 
Cells were treated with 5 mM sodium azide for 5 h.  Cells were then either  immediately fixed (a) or allowed to recover from treatment 
in growth medium, in the presence of CF, for 6 h (b). Sodium azide treatment completely dispersed the AChR clusters, although punctate 
labeling was still present on some cells (a). After replacement of medium, cells were able to reform clusters (b). (c-h) Cells were treated 
as described above, but before recovery they were injected with either D3-16 (c and d), MIg (e and f), or antitubulin (g and h). D3-16-in- 
jected cells did not form clusters after recovery from sodium azide treatment.  The ability to reform clusters was not lost by MIg- and 
antitubulin-injected  cells.  Bar, 10 #m. 
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